You are currently viewing our site as a guest, which gives you limited access to our site features. By signing up for a free membership, you will receive our Investment Opportunity newsletters and have access to additional features for finding and comparing managed funds and shares. Registration is fast and simple, so please:
Business Description: Agenix Limited (AGX) is an Australian based international biotechnology company with a wholly owned subsidiary in China. The company has two core businesses: Innovative Biopharmaceuticals and Medical Diagnostics
Strategy Analysis: As part of the organic growth strategy Agenix will continue to invest funds in the commercialisation Thromboview (TB) product. The company plans to spend more than $10m in FY06 on the progress of Thromboview. As part of their strategy, Agenix enters into manufacturing and distribution contracts with third parties. Agenix's subsidary, Milton Pharmaceuticlas, was sold in FY05 to free management and financial resources to build the imaging pipeline.
In addition, Agenix focuses on broadening its products portfolio with preliminary work commencing on the development of a product to image arterial blood clots associated with heart attacks and strokes..
The Age 26/05/2012 | I WAS reading some old Marcus Today newsletters. From 2003. Let me take you back and allow you to exercise the power of hindsight:
The Age 25/05/2012 | RADIO People are six times more likely to go to an advertiser's website if they have heard the ad on radio, according to research by Colmar Brunton, released by Commercial Radio Australia. The research showed that radio advertising has an immediate effect on people's digital activity, with more than three-quarters of those exposed to advertising visiting a website or Facebook page or searching for the brand online within 24 hours. Commercial Radio Australia chief executive Joan Warner said the ...
Already a member? 
$ 0.004
